Late effects following CAR T cells and HCT in children and young adults with B-cell acute lymphoblastic leukemia

Affiliations

Bonnie Yates et al. Blood Immunol Cell Ther. 2025 Sep.

. 2025 Sep;1(2):100008.

doi: 10.1016/j.bict.2025.100008. Epub 2025 Aug 12.

¹ Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health (NIH), Bethesda, MD, USA.

No abstract available

Keywords: acute lymphoblastic leukemia; chimeric antigen receptor T-cells; immunotherapy; late effects; relapse.

References

1. Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019;25(4):625–38. - PMC - PubMed
1. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023;29(7):438 e1–e16.
1. Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, et al. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024;8(8):1857–68. - PMC - PubMed
1. Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL. J Clin Oncol. 2021;39(15):1650–9. - PMC - PubMed
1. John S, Curran KJ, Hall EM, Keating A, Baumeister SHC, Nikiforow S, et al. Real-world data for tisagenlecleucel in patients with R/R B-ALL: subgroup analyses from the CIBMTR registry. Blood Adv. 2025.